Human Papillomavirus Prevalence Among American Indian Women of the Great Plains.
American Indians
genotype distribution
human papillomavirus (HPV)
human papillomavirus vaccination
self-sampling
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
23 02 2019
23 02 2019
Historique:
received:
25
06
2018
accepted:
08
10
2018
pubmed:
16
10
2018
medline:
9
1
2020
entrez:
16
10
2018
Statut:
ppublish
Résumé
High-risk human papillomavirus (hrHPV) causes cervical cancer. In the United States, approximately 40% of women aged 14-59 years from all racial and ethnic groups are infected with HPV, and prevalence typically declines with age. However, American Indian (AI) women are insufficiently sampled to permit a population-specific estimate of hrHPV prevalence. Vaginal swabs were self-collected by 698 AI women aged 21-65 years from a tribal community in the Great Plains. We estimated the population prevalence of hrHPV and identified predominant genotypes. The combined prevalence of hrHPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 was 34.8%. HPV-51 (7.6%), HPV-58 (5.3%), HPV-52 (4.3%), HPV-18 (4.3%), and HPV-16 (3.9%) were most prevalent. hrHPV prevalence declined with age, from 42.2% in women aged 21-24 years to 27.9% in women aged 50-65 years. HPV-51 was the single most prevalent oncogenic genotype. The combined prevalence of hrHPV among AI women in our sample was high, particularly among women aged 50-65 years, for whom hrHPV prevalence was approximately triple that of other races. Cervical cancer screening efforts should be increased, particularly among women from the community aged 30 years and older.
Sections du résumé
BACKGROUND
High-risk human papillomavirus (hrHPV) causes cervical cancer. In the United States, approximately 40% of women aged 14-59 years from all racial and ethnic groups are infected with HPV, and prevalence typically declines with age. However, American Indian (AI) women are insufficiently sampled to permit a population-specific estimate of hrHPV prevalence.
METHODS
Vaginal swabs were self-collected by 698 AI women aged 21-65 years from a tribal community in the Great Plains. We estimated the population prevalence of hrHPV and identified predominant genotypes.
RESULTS
The combined prevalence of hrHPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 was 34.8%. HPV-51 (7.6%), HPV-58 (5.3%), HPV-52 (4.3%), HPV-18 (4.3%), and HPV-16 (3.9%) were most prevalent. hrHPV prevalence declined with age, from 42.2% in women aged 21-24 years to 27.9% in women aged 50-65 years.
CONCLUSIONS
HPV-51 was the single most prevalent oncogenic genotype. The combined prevalence of hrHPV among AI women in our sample was high, particularly among women aged 50-65 years, for whom hrHPV prevalence was approximately triple that of other races. Cervical cancer screening efforts should be increased, particularly among women from the community aged 30 years and older.
Identifiants
pubmed: 30321371
pii: 5131631
doi: 10.1093/infdis/jiy600
pmc: PMC6386810
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
908-915Subventions
Organisme : NIGMS NIH HHS
ID : K12 GM088021
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG015292
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA143925
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
BMC Infect Dis. 2014 Feb 21;14:96
pubmed: 24559293
Int J Cancer. 2013 Jan 1;132(1):198-207
pubmed: 22532127
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9
pubmed: 20508593
J Natl Cancer Inst. 2005 May 4;97(9):675-83
pubmed: 15870438
Gynecol Oncol. 2011 Jun 1;121(3):532-6
pubmed: 21414655
Virology. 2013 Oct;445(1-2):2-10
pubmed: 23683837
Cancer Prev Res (Phila). 2012 Jan;5(1):18-23
pubmed: 22219162
J Infect Dis. 2015 Dec 15;212(12):1970-5
pubmed: 26123561
Hum Vaccin Immunother. 2015;11(10):2337-44
pubmed: 26376014
Methods Mol Biol. 2012;903:205-23
pubmed: 22782820
Am J Epidemiol. 2003 Feb 1;157(3):218-26
pubmed: 12543621
Adv Exp Med Biol. 1993;330:13-26
pubmed: 8396309
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Health Educ Behav. 2013 Dec;40(6):704-11
pubmed: 23460671
Front Public Health. 2015 Dec 17;3:256
pubmed: 26734596
J Gerontol B Psychol Sci Soc Sci. 2009 Nov;64 Suppl 1:i106-18
pubmed: 19204072
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
J Community Health. 2016 Oct;41(5):1049-61
pubmed: 27048284
Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S2-5
pubmed: 17938014
West J Med. 1992 Apr;156(4):376-9
pubmed: 1574879
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10
pubmed: 16949995
J Cancer Educ. 2013 Jun;28(2):357-66
pubmed: 23564429
Gynecol Oncol. 2007 Nov;107(2):236-41
pubmed: 17659767
J Infect Dis. 2018 Mar 5;217(6):869-877
pubmed: 29294016
Vaccine. 2013 Dec 31;31 Suppl 7:H1-31
pubmed: 24332295
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
BMC Infect Dis. 2011 Sep 24;11:252
pubmed: 21943050
Vaccine. 2012 Nov 20;30 Suppl 5:F55-70
pubmed: 23199966
Pediatrics. 2016 Mar;137(3):e20151968
pubmed: 26908697
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8
pubmed: 27561081
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
BMC Res Notes. 2014 Aug 18;7:544
pubmed: 25134828
J Infect Dis. 2017 Sep 1;216(5):594-603
pubmed: 28931217
J Infect Dis. 2013 Aug 1;208(3):385-93
pubmed: 23785124
Am J Public Health. 2014 Jun;104 Suppl 3:S415-22
pubmed: 24754650
Am J Prev Med. 2017 Aug;53(2):162-168
pubmed: 28256284
Oncol Lett. 2016 Jul;12(1):601-610
pubmed: 27347187